Sana Biotechnology's Hypoimmune Cell Therapy Shows Promise in Type 1 Diabetes
• Sana Biotechnology's UP421 demonstrated survival and function of transplanted pancreatic beta cells in a type 1 diabetes patient without immunosuppression.
• The first-in-human study showed increased C-peptide levels, indicating insulin production, and sustained signals at the transplant site via MRI.
• TD Cowen upgraded Sana Biotechnology to Buy, noting the results meaningfully derisk type 1 diabetes and other applications of the Hypoimmune platform.
• The company's stock price surged following the release of the positive data, reflecting investor optimism about the potential of the new treatment.
© Copyright 2025. All Rights Reserved by MedPath